Daiichi Sankyo Company, Limited

Kengo Noguchi

Tsutomu Nagata

Makoto Ono

Masahiro Inoue

Jun Kobayashi

Yoshiyuki Onishi

Masamichi Kishida

Yuka Ashida

Yusuke Ito

Naoko Edo

The present invention provides a pharmaceutical composition for treatment or prevention of thrombosis or embolism or a sequela thereof, comprising a particular TAFIa inhibitor and a plasminogen activator, the TAFIa inhibitor being administered in combination with the plasminogen activator, and a method for treating or preventing thrombosis or embolism or a sequela thereof, comprising administering a particular TAFIa inhibitor in combination with a plasminogen activator to a warm-blooded animal.

Combination of TAFIa inhibitor with plasminogen activator

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein Rrepresents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R, R, and Reach independently represent a hydrogen atom or a C1 to C3 alkyl group; R, R, R, R, R, and Reach independently represent a hydrogen atom or the like; and Rrepresents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.

Cyclopropanecarboxylic acid derivative

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R, R, and Reach independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; Rrepresents a hydrogen atom or a prodrug group; and Y represents &#x2014;CH&#x2014;CHR&#x2014;CH&#x2014;NHR(wherein Rrepresents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and Rrepresents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

Cycloalkyl-substituted imidazole derivative

Growing community of inventors

Tokyo, Japan

Kengo Noguchi